Status:
COMPLETED
Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease
Lead Sponsor:
Bastiaan Driehuys
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Children's Hospital Medical Center, Cincinnati
Conditions:
Interstitial Lung Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung disea...
Eligibility Criteria
Inclusion
- Inclusion/Exclusion Criteria for Healthy Volunteers
- Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
- Outpatients of either gender, age greater than or equal to 18 years
- Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed.)
- Subject has no diagnosed pulmonary conditions
- Subject has not smoked in the previous 5 years
- Smoking history, if any, is less than or equal to 5 pack-years
- No history of using other inhaled products more than 1 time per week for \> 1 year
Exclusion
- Subjects presenting with any of the following will not be included in the trial:
- Subject is less than 18 years old
- MRI is contraindicated based on responses to MRI screening questionnaire
- Subject is pregnant or lactating
- Resting oxygen saturation on room air \<90%
- Respiratory illness of a bacterial or viral etiology within 30 days of MRI
- Subject has history of any known ventricular cardiac arrhythmia
- Subject has history of cardiac arrest within the last year
- Subject does not fit into Xe vest coil used for MRI 129
- Subject cannot hold his/her breath for 15 seconds
- Subject deemed unlikely to be able to comply with instructions during imaging
- Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
- Inclusion/Exclusion Criteria for Subjects with Interstitial Lung Disease
- Inclusion Criteria: Subjects must meet all of the following inclusion criteria to be eligible for enrollment in the trial:
- Outpatients of either gender, age greater than or equal to 18 years
- Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed.)
- Clinical diagnosis of Interstitial Lung Disease made by a board certified pulmonologist using established criteria. We will not exclude individuals based on ILD type or severity of disease with the exception of the below criteria
Key Trial Info
Start Date :
November 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 11 2025
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04855305
Start Date
November 12 2021
End Date
June 11 2025
Last Update
November 21 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Iowa
Iowa City, Iowa, United States, 52242
2
Duke University Medical Center
Durham, North Carolina, United States, 27710
3
University of Cincinnati
Cincinnati, Ohio, United States, 45219
4
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229